Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains most...

Descripción completa

Detalles Bibliográficos
Autores principales: Kachmazov, Andrei, Bolotina, Larisa, Kornietskaya, Anna, Kuznetsova, Olesya, Ivanov, Maxim, Fedenko, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478540/
https://www.ncbi.nlm.nih.gov/pubmed/36119518
http://dx.doi.org/10.3389/fonc.2022.953908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478540/
https://www.ncbi.nlm.nih.gov/pubmed/36119518
http://dx.doi.org/10.3389/fonc.2022.953908

Ejemplares similares